Regeneron halts phase 3 plans for aflibercept combo therapy
- Posted on: Nov 28 2017
On the heels of disappointing phase 2 results, Regeneron Pharmaceuticals, Inc. says it will discontinue development of their aflibercept/nesvacumab combination therapy for diabetic macular edema (DME) and wet AMD.
Source: AAO
Posted in: Practice News
